Results 81 to 90 of about 135,111 (338)

Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk, Ewa Dziewięcka, Sylwia Wiśniowska‐Śmiałek, Agnieszka Stępień, Katarzyna Graczyk, Agata Leśniak‐Sobelga, Marta Hlawaty, Jakub Woźniak, Maryia Savitskaya, Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś   +12 more
wiley   +1 more source

PROPAFENONE FOR SINUS RHYTHM RECOVERY AND SUPPORT IN PATIENTS WITH PERSISTENT FORM OF AURICULAR FIBLILLATION. “PROMETHEUS” – OPENED MULTICENTER STUDY IN RUSSIAN FEDERATION

Рациональная фармакотерапия в кардиологии, 2016
Aim. To study efficiency and safety of propafenone internally used for recovery and support of sinus rhythm in patients with the persistent form of auricular fibrillation (AF). Material and methods. 503 patients with the persistent form of AF, aged 31-68
I. G. Fomina, A. I. Tarzimanova, A. V. Vetluzsky   +2 more
doaj   +2 more sources

Atypical Pre-excitation Pattern in Asymptomatic Wolff-Parkinson-White—A Hallmark for High Risk?

Romanian Journal of Cardiology
Delta wave morphology during sinus rhythm on 12 lead ECG usually allows for a relatively precise prediction of the anatomic location of an accessory pathway (AP) provided that the rhythm is fully pre-excited.
Burcin Alexandru-Paul, Ene Elena, Vătăşescu Radu-Gabriel   +2 more
doaj   +1 more source

STATE OF THE ART PHARMACOLOGICAL THERAPY FOR ATRIAL FIBRILLATION

Российский кардиологический журнал, 2017
Pharmacological therapy remains the primary approach to atrial fibrillation (AF). Management of all AF patients includes the decision on rate or rhythm control. The latter means antiarrhythmic drugs application that are being selected primarily by safety
S. G. Kanorsky, Yu. S. Kovalenko
doaj   +1 more source

Automatic Mode Switching in Atrial Fibrillation [PDF]

, 2005
Automatic mode switching (AMS) algorithms were designed to prevent tracking of atrial tachyarrhythmias (ATA) or other rapidly occurring signals sensed by atrial channels, thereby reducing the adverse hemodynamic and symptomatic consequences of a rapid ...
Antonio De, Simone, Enrico, Romano, Giuseppe, Stabile   +2 more
core  

How random is your heart beat? [PDF]

, 2006
We measure the content of random uncorrelated noise in heart rate variability using a general method of noise level estimation using a coarse grained entropy.
Baselli, Bayés da Luna, Cencini, Costa, Denton, Eke, Grassberger, Groome, He, Jan J. Żebrowski, Janusz A. Hołyst, Krzysztof Urbanowicz, Kuusela, Kuusela, Marwan, Naschitz, Rafał Baranowski, Stanley, Stanley, Stein, Stein, Thiel, Urbanowicz, Urbanowicz, Voss, Wei, Wu, Yulmetyev, Żebrowski, Żebrowski, Żebrowski   +30 more
core   +2 more sources

Ibutilide with magnesium for conversion of atrial fibrillation or flutter in rheumatic heart disease patients

Indian Heart Journal, 2020
Background: Data on adjunctive use of magnesium with ibutilide for conversion of persistent rheumatic atrial fibrillation and flutter to sinus rhythm is lacking.
Amit Malviya, Manish Kapoor, Rondeep kumar Nath Sivam, Shakeel Ahamad Khan, Ruchi Pandey, Utpal Kumar, Tony Ete, Animesh Mishra   +7 more
doaj  

A pairwise maximum entropy model describes energy landscape for spiral wave dynamics of cardiac fibrillation

, 2018
Heart is an electrically-connected network. Spiral wave dynamics of cardiac fibrillation shows chaotic and disintegrated patterns while sinus rhythm shows synchronized excitation patterns.
Pak, Hui-Nam, Song, Jun-Seop, Song, Tobias G.   +2 more
core  

RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers [PDF]

, 2012
BACKGROUND Atrial fibrillation is a serious public health problem posing a considerable burden to not only patients, but the healthcare environment due to high rates of morbidity, mortality, and medical resource utilization. There are limited data on the
AJ Camm, Aldo P Maggioni, Alexandra A Bernhardt, Alfonso Martín, Anselm K Gitt, AS Go, B Lown, BN Singh, CA Sanoski, CX Wong, François Chazelle, Gregory YH Lip, GV Naccarelli, H Stefansdottir, Harry JGM Crijns, Hemant M Phatak, IC Van Gelder, IC Van Gelder, J Heeringa, Jean-Yves Le Heuzey, JML Hendriks, K Wachtell, Lori D Bash, Mauricio Scanavacca, MM Gallagher, Mårten Rosenqvist, P Alboni, Piotr Ponikowski, Prashanthan Sanders, R Pisters, RG Tieleman, S DeWilde, Sreevalsa Unniachan, T Meinertz, Thorsten Lewalter, VE Hagens, Y Miyasaka   +36 more
core   +3 more sources

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source